Alice Nervo1, Marco Gallo2, Maria Teresa Samà2, Francesco Felicetti2, Martina Alfano2, Enrica Migliore3, Filippo Marchisio4, Rita Berardelli2, Emanuela Arvat2, Alessandro Piovesan2. 1. Oncological Endocrinology Unit, Department of Medical Sciences, Città della Salute e della Scienza Hospital, Turin, Italy alice.nervo@gmail.com. 2. Oncological Endocrinology Unit, Department of Medical Sciences, Città della Salute e della Scienza Hospital, Turin, Italy. 3. Cancer Epidemiology Unit, Department of Medical Sciences, University of Torino, Turin, Italy. 4. Diagnostic and Interventional Radiology Unit, Department of Diagnostic Imaging and Radiotherapy, Città della Salute e della Scienza Hospital, Turin, Italy.
Abstract
BACKGROUND: We retrospectively analyzed the efficacy and safety of lenvatinib in 12 patients with advanced radioiodine-refractory thyroid cancer in the setting of daily clinical practice. PATIENTS AND METHODS: The starting daily dose of lenvatinib was 24 mg, tapered in the case of adverse events. Disease status was periodically evaluated by a single radiologist and safety assessment was regularly performed. RESULTS: After a median follow-up of 13.3 months, 6- and 12-month progression-free survival rates were 63.6% and 54.6%, respectively. Overall survival at 6 and 12 months was 83.3% and 75.0%. Partial response was observed in five patients, while two showed stable disease as their best response. Conversely, progressive disease at first radiological assessment was detected in four patients. All patients experienced at least one adverse event, including systemic and gastrointestinal toxicity, high blood pressure and hand-foot syndrome. In order to manage toxicity, transient drug interruption and dose reduction were required in 10 and 9 cases, respectively. CONCLUSION: Our data confirm lenvatinib efficacy in patients with advanced thyroid cancer, despite an important toxic profile. Copyright
BACKGROUND: We retrospectively analyzed the efficacy and safety of lenvatinib in 12 patients with advanced radioiodine-refractory thyroid cancer in the setting of daily clinical practice. PATIENTS AND METHODS: The starting daily dose of lenvatinib was 24 mg, tapered in the case of adverse events. Disease status was periodically evaluated by a single radiologist and safety assessment was regularly performed. RESULTS: After a median follow-up of 13.3 months, 6- and 12-month progression-free survival rates were 63.6% and 54.6%, respectively. Overall survival at 6 and 12 months was 83.3% and 75.0%. Partial response was observed in five patients, while two showed stable disease as their best response. Conversely, progressive disease at first radiological assessment was detected in four patients. All patients experienced at least one adverse event, including systemic and gastrointestinal toxicity, high blood pressure and hand-foot syndrome. In order to manage toxicity, transient drug interruption and dose reduction were required in 10 and 9 cases, respectively. CONCLUSION: Our data confirm lenvatinib efficacy in patients with advanced thyroid cancer, despite an important toxic profile. Copyright
Authors: Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit Journal: Eur Thyroid J Date: 2019-08-28
Authors: Matti L Gild; Venessa H M Tsang; Roderick J Clifton-Bligh; Bruce G Robinson Journal: Nat Rev Endocrinol Date: 2021-02-18 Impact factor: 43.330
Authors: F Platini; S Cavalieri; S Alfieri; C Bergamini; C Resteghini; A Bottiglieri; E Colombo; L Mazzeo; L Licitra; B Paolini; E Seregni; L D Locati Journal: Endocrine Date: 2021-04-02 Impact factor: 3.633
Authors: Ole Vincent Ancker; Marcus Krüger; Markus Wehland; Manfred Infanger; Daniela Grimm Journal: Int J Mol Sci Date: 2019-12-18 Impact factor: 5.923